- SourceMouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Rituximab F(ab")2.
- IsotypeIgG1/kappa
- SpecificityRecognizes Rituximab specifically, no cross reactivity with other humanized antibodies.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 years under sterile conditions after reconstitution.
Anti-Rituximab Antibodies (recommended for ADA assay) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Anti-Rituximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized rituximab at 1 µg/mL, add increasing concentrations of Anti-Rituximab Antibodies (Cat. No. RIB-Y36, 10% human serum) and then add biotinylated rituximab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9.7 ng/mL.
Demonstration of the specificity of Anti-Rituximab Antibodies (Cat. No. RIB-Y36) to the rituximab.
Anti-Rituximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized rituximab at 1 µg/mL, add increasing concentrations of Anti-Rituximab Antibodies (Cat. No. RIB-Y36, 10% human serum) and then add biotinylated rituximab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9.7 ng/mL.
Anti-Rituximab Antibodies (mouse IgG1, Cat. No. RIB-Y36) captured on CM5 chip via anti-mouse antibodies surface, can bind human rituximab with an affinity constant of 0.01 nM.
FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibodies (Cat. No. RIB-Y36). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.025 μg/ml (Routinely tested).
- BackgroundRituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
AcroBiosystems是专注于生物药开发过程的蛋白技术和产品的全球化品牌，目前位于美国特拉华州的纽瓦克市，是一家专业研发、生产、销售蛋白相关分子生物学试剂的高科技公司。AcroBiosystems从成立之初至今一直致力于提供在药物研发过程中所需的高质量的靶点蛋白，满足市场对大批量、高批间*性的蛋白试剂的需求，产品和服务面向全球制药公司、生物技术公司及科研院所。产品包括免疫检查点蛋白、生物素标记蛋白、Fc受体蛋白、CAR-T靶点蛋白等，基于AviTagTM标记技术和化学标记技术的生物素标记蛋白系列被广泛应用于Biacore，AlphaLisa，MSD等平台。这些产品受到了学术界的*好评。
CD Feed X Supplement Plus, Liquid No.CF-1116
产品介绍
品牌：acrobiosystems
规格：500ml
产品描述：CD细胞的生长的补充液是化学定义的，能显著提高细胞密度和延长细胞活力，从而增加靶蛋白的表达，使用剂量为5-10%（V/V）。与CD 293 TGE培养基配合使用，BPM-BPfectin和293-Expression MAX-1可提高蛋白表达量。
产品特性：① 显著提高生产率
② 无动物源、无蛋白质、无血清和化学成分
储存条件：2℃-8℃，避光。
产品参数：
部分产品的详细列表：AcroBiosystems授权代理
货号 | 产品 | 规格 | 价格（美元） |
BAF-HF268 | FITC-Labeled Human BAFF / TNFSF13B / CD257 Protein, Fc Tag | 25ug | $290 |
BCA-HF254 | FITC-Labeled Human BCMA, Fc Tag | 25ug | $290 |
BCA-HF2H1 | FITC-Labeled Human BCMA, His Tag | 25ug | $290 |
![ACROBiosystems/Influenza A[A/swine/Jiangsu/J004/2018(H1N1)] Hemagglutinin (HA) Protein, His Tag/1mg/HEN](images/no_picture.gif)
暂无问答
本网站将在规定时间内给予删除等相关处理。
